Compare Aurora Cannabis Inc (ACB) vs MobilEye Global Inc (MBLY) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Mobileye (MBLY) trades at $10.00, up 4.49% today, with a bullish technical signal from moving averages and strong analyst support. The stock shows negative profitability with a net income margin of -203.97% in 2026 but maintains solid revenue growth, reaching $2.0B. Recent news highlights its strategic shift to launch a vertically integrated U.S. robotaxi service in 2027, positioning it against competitors like Waymo and Tesla.

The outlook is cautiously optimistic due to the robotaxi initiative's potential, but high execution risks and persistent losses pose challenges. Analysts project a consensus price target of $10.36, with 57.69% recommending Buy. Investors should weigh the growth opportunity against the company's current unprofitability and competitive pressures in the autonomous vehicle sector.